Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SonaCare Medical LLC

www.ushifu.com

Latest From SonaCare Medical LLC

Market Brief: The Global Market For Prostate Cancer Diagnostics Will Reach $460.5M In 2023

The global market for prostate cancer diagnostics is expected to see double-digit growth, reaching $460.5m in 2023 and is driven by new technologies, in particular liquid biopsies and new genetic marker tests, according to a new report by Informa's Meddevicetracker.

Innovation Market Intelligence

US FDA Asks Prostate Ablation Device-Sponsors For More Clinical Safety Data To Support Clearances

Almost four years after the agency first authorized a prostate ablation device, regulators have proposed a number of requirements for clinical studies that sponsors would have to meet to comply with special controls needed for the devices to be cleared for marketing.

Regulation Guidance Documents

Market Intel: New Thermal Therapies Blaze Trail In Fast-Growing Cancer Ablation Market

Cancer rates are rising worldwide and as diagnostic techniques continue to improve, new surgical ablation devices are becoming crucial weapons in the growing arsenal of cancer treatment tools. These devices allow doctors to burn away tumors with precision, speed and safety, without the side-effects that patients undergoing radical cancer therapy often experience. This article provides an overview of the cancer ablation market, highlights the key players working on these devices and discusses their potential applications. It also includes critical insights from a leading interventional urologist on the pros and cons of using these various technologies in treating prostate cancer.

Cancer Surgical Procedures

HIFU Face-Off: US Competition Begins For Prostate High-Intensity Focused Ultrasound

With the 510(k) clearance of EDAP TMS' Ablatherm HIFU and the first US procedure performed with SonaCare Medical's recently cleared Sonablate system, a European rivalry in high-intensity focused ultrasound machines for prostate cancer has moved to the US. And EDAP's CEO argues it was positive for long-term adoption that his firm's system ultimately gained 510(k) clearance as a surgical tool rather than the originally sought PMA approval for a prostate cancer indication.

Medical Device Regulation
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Ultrasound
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • US HIFU LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • SonaCare Medical LLC
  • Senior Management
  • Michael Klein, CEO
    Naren Sanghvi, PhD, CSO
    John Linn, VP, Fin.
  • Contact Info
  • SonaCare Medical LLC
    Phone: (704) 332-4308
    801 E. Morehead St.
    Ste. 201
    Charlotte, NC 28202
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register